Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. … Read more
My top 10 things to watch Monday, May 19 1. Bonds are crushing stocks this morning, with the 30-year Treasury yield north of 5% and the 10-year Treasury yield topping 4.5%, in response to Moody’s downgrading its rating on U.S. sovereign debt. The S & P 500 is on track to open lower by about … Read more
Many of the biggest U.S. companies have pledged to invest trillions of dollars in the United States since President Donald Trump started his second term — including six names in our portfolio. These moves are aimed at aligning companies with the president’s vision for a new global trade order designed to bring manufacturing jobs back … Read more
Bristol Myers Squibb ‘s earnings beat and rosy outlook Thursday did not resolve lingering issues for the stock. But it was enough, for now. Revenue in the first quarter, which ended March 31, dipped 6% to $11.2 billion but topped estimates of $10.7 billion, according to LSEG. Adjusted earnings per share of $1.80 beat expectations … Read more
Danaher shares on Tuesday climbed more than 6% after the health-care company’s first-quarter results exceeded expectations — and, crucially, its guidance was left mostly intact despite an evolving economic picture. Count us among the investors breathing a sigh of relief. Revenue for the three months ended March 31 declined 1% year over year to $5.74 … Read more
The stock market heads into Monday on a streak of volatility it just can’t seem to shake. What had been shaping up as a positive holiday-shortened week turned on a dime Wednesday when Federal Reserve Chairman Jerome Powell signaled concern that President Donald Trump ‘s tariffs could increase inflation and slow economic growth. Speaking at … Read more
Eli Lilly is tightening its grip on the lucrative weight-loss market as it moves into a new, more convenient phase that promises to broaden the appeal of its breakthrough drugs. The news Club name Lilly said its daily obesity pill was successful in a late-stage trial for Type 2 diabetes — sending shares soaring more … Read more
Shares of Abbott Laboratories jumped Wednesday after the diversified health-care company delivered strong first-quarter results and left its earnings guidance intact — a big sign of confidence in an uncertain time. Revenue in the three months ended March 31 rose 4% to $10.36 billion, narrowly missing the consensus of $10.4 billion, according to estimates compiled … Read more
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. Wall Street surged Tuesday on increased hopes of tariff deals, following a wickedly volatile session Monday. The Dow Jones Industrial Average climbed around 1,400 points, or 3.7%. The S … Read more
Shortly after the opening bell, we will be exiting our position in GE Healthcare , selling 550 shares at roughly $65. Following Friday’s trade, Jim Cramer’s Charitable Trust will no longer own a position in GEHC. We’re cutting loose our small position in GE Healthcare and raising some cash following two negative developments over the … Read more